![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DDB2 |
Gene summary for DDB2 |
![]() |
Gene information | Species | Human | Gene symbol | DDB2 | Gene ID | 1643 |
Gene name | damage specific DNA binding protein 2 | |
Gene Alias | DDBB | |
Cytomap | 11p11.2 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q92466 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1643 | DDB2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.33e-09 | 6.62e-01 | -0.0811 |
1643 | DDB2 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.20e-02 | 3.49e-01 | -0.1088 |
1643 | DDB2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.25e-08 | 6.56e-01 | -0.059 |
1643 | DDB2 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.25e-03 | 2.69e-01 | 0.096 |
1643 | DDB2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.11e-02 | 3.73e-01 | 0.0588 |
1643 | DDB2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.67e-02 | 3.30e-01 | 0.3005 |
1643 | DDB2 | A015-C-203 | Human | Colorectum | FAP | 2.79e-03 | -6.81e-02 | -0.1294 |
1643 | DDB2 | A015-C-104 | Human | Colorectum | FAP | 1.10e-02 | -8.53e-02 | -0.1899 |
1643 | DDB2 | LZE4T | Human | Esophagus | ESCC | 5.16e-07 | 2.00e-01 | 0.0811 |
1643 | DDB2 | LZE8T | Human | Esophagus | ESCC | 8.97e-03 | 1.66e-01 | 0.067 |
1643 | DDB2 | LZE20T | Human | Esophagus | ESCC | 2.76e-06 | 1.41e-01 | 0.0662 |
1643 | DDB2 | LZE22D1 | Human | Esophagus | HGIN | 6.66e-03 | 1.20e-01 | 0.0595 |
1643 | DDB2 | LZE24T | Human | Esophagus | ESCC | 5.52e-07 | 4.58e-01 | 0.0596 |
1643 | DDB2 | P1T-E | Human | Esophagus | ESCC | 4.46e-06 | 3.69e-01 | 0.0875 |
1643 | DDB2 | P2T-E | Human | Esophagus | ESCC | 2.18e-30 | 6.08e-01 | 0.1177 |
1643 | DDB2 | P4T-E | Human | Esophagus | ESCC | 5.57e-16 | 2.38e-01 | 0.1323 |
1643 | DDB2 | P5T-E | Human | Esophagus | ESCC | 1.02e-09 | 6.88e-02 | 0.1327 |
1643 | DDB2 | P8T-E | Human | Esophagus | ESCC | 2.15e-09 | 2.50e-01 | 0.0889 |
1643 | DDB2 | P9T-E | Human | Esophagus | ESCC | 1.02e-09 | 1.67e-01 | 0.1131 |
1643 | DDB2 | P10T-E | Human | Esophagus | ESCC | 3.66e-19 | 3.41e-01 | 0.116 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0000209 | Colorectum | AD | protein polyubiquitination | 78/3918 | 236/18723 | 8.71e-06 | 2.06e-04 | 78 |
GO:0051865 | Colorectum | AD | protein autoubiquitination | 28/3918 | 73/18723 | 4.87e-04 | 5.30e-03 | 28 |
GO:0033522 | Colorectum | AD | histone H2A ubiquitination | 12/3918 | 26/18723 | 3.47e-03 | 2.51e-02 | 12 |
GO:0006513 | Colorectum | AD | protein monoubiquitination | 23/3918 | 67/18723 | 7.55e-03 | 4.58e-02 | 23 |
GO:00002092 | Colorectum | MSS | protein polyubiquitination | 72/3467 | 236/18723 | 5.19e-06 | 1.42e-04 | 72 |
GO:0016570 | Colorectum | MSS | histone modification | 113/3467 | 463/18723 | 8.37e-04 | 8.68e-03 | 113 |
GO:00518651 | Colorectum | MSS | protein autoubiquitination | 25/3467 | 73/18723 | 1.00e-03 | 1.00e-02 | 25 |
GO:00335221 | Colorectum | MSS | histone H2A ubiquitination | 12/3467 | 26/18723 | 1.16e-03 | 1.12e-02 | 12 |
GO:00065131 | Colorectum | MSS | protein monoubiquitination | 21/3467 | 67/18723 | 7.90e-03 | 4.84e-02 | 21 |
GO:0016574 | Colorectum | MSS | histone ubiquitination | 16/3467 | 47/18723 | 8.22e-03 | 4.99e-02 | 16 |
GO:00002093 | Colorectum | FAP | protein polyubiquitination | 59/2622 | 236/18723 | 4.53e-06 | 1.52e-04 | 59 |
GO:00165701 | Colorectum | FAP | histone modification | 94/2622 | 463/18723 | 1.06e-04 | 1.76e-03 | 94 |
GO:00518652 | Colorectum | FAP | protein autoubiquitination | 22/2622 | 73/18723 | 2.88e-04 | 3.77e-03 | 22 |
GO:00335222 | Colorectum | FAP | histone H2A ubiquitination | 10/2622 | 26/18723 | 1.77e-03 | 1.53e-02 | 10 |
GO:00165741 | Colorectum | FAP | histone ubiquitination | 14/2622 | 47/18723 | 3.95e-03 | 2.75e-02 | 14 |
GO:00065132 | Colorectum | FAP | protein monoubiquitination | 18/2622 | 67/18723 | 4.08e-03 | 2.81e-02 | 18 |
GO:0071214 | Colorectum | FAP | cellular response to abiotic stimulus | 63/2622 | 331/18723 | 6.38e-03 | 3.99e-02 | 63 |
GO:0104004 | Colorectum | FAP | cellular response to environmental stimulus | 63/2622 | 331/18723 | 6.38e-03 | 3.99e-02 | 63 |
GO:000020916 | Esophagus | HGIN | protein polyubiquitination | 58/2587 | 236/18723 | 6.29e-06 | 1.97e-04 | 58 |
GO:00165708 | Esophagus | HGIN | histone modification | 92/2587 | 463/18723 | 1.70e-04 | 3.30e-03 | 92 |
Page: 1 2 3 4 5 6 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0522216 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
hsa0521638 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
hsa0516114 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa05213110 | Esophagus | ESCC | Endometrial cancer | 45/4205 | 58/8465 | 1.14e-05 | 5.98e-05 | 3.06e-05 | 45 |
hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa0521418 | Esophagus | ESCC | Glioma | 52/4205 | 75/8465 | 4.20e-04 | 1.45e-03 | 7.43e-04 | 52 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0522316 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa0516928 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa0412020 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
hsa0521210 | Oral cavity | OSCC | Pancreatic cancer | 60/3704 | 76/8465 | 3.32e-10 | 4.45e-09 | 2.26e-09 | 60 |
hsa0521018 | Oral cavity | OSCC | Colorectal cancer | 66/3704 | 86/8465 | 3.99e-10 | 4.95e-09 | 2.52e-09 | 66 |
hsa041159 | Oral cavity | OSCC | p53 signaling pathway | 57/3704 | 74/8465 | 4.99e-09 | 5.07e-08 | 2.58e-08 | 57 |
hsa034204 | Oral cavity | OSCC | Nucleotide excision repair | 49/3704 | 63/8465 | 3.48e-08 | 2.91e-07 | 1.48e-07 | 49 |
hsa052228 | Oral cavity | OSCC | Small cell lung cancer | 66/3704 | 92/8465 | 4.43e-08 | 3.38e-07 | 1.72e-07 | 66 |
hsa0522018 | Oral cavity | OSCC | Chronic myeloid leukemia | 56/3704 | 76/8465 | 1.04e-07 | 7.43e-07 | 3.78e-07 | 56 |
hsa051618 | Oral cavity | OSCC | Hepatitis B | 103/3704 | 162/8465 | 2.34e-07 | 1.51e-06 | 7.69e-07 | 103 |
hsa0521318 | Oral cavity | OSCC | Endometrial cancer | 40/3704 | 58/8465 | 8.86e-05 | 3.19e-04 | 1.62e-04 | 40 |
hsa0521410 | Oral cavity | OSCC | Glioma | 49/3704 | 75/8465 | 1.27e-04 | 4.50e-04 | 2.29e-04 | 49 |
hsa0522516 | Oral cavity | OSCC | Hepatocellular carcinoma | 97/3704 | 168/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 97 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDB2 | SNV | Missense_Mutation | c.716N>A | p.Arg239Lys | p.R239K | Q92466 | protein_coding | tolerated(0.99) | benign(0.049) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
DDB2 | deletion | Frame_Shift_Del | novel | c.1034delA | p.His345LeufsTer25 | p.H345Lfs*25 | Q92466 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
DDB2 | SNV | Missense_Mutation | c.807N>G | p.Ile269Met | p.I269M | Q92466 | protein_coding | tolerated(0.09) | possibly_damaging(0.732) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
DDB2 | SNV | Missense_Mutation | novel | c.145N>C | p.Asp49His | p.D49H | Q92466 | protein_coding | deleterious(0.01) | possibly_damaging(0.674) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
DDB2 | SNV | Missense_Mutation | rs375649516 | c.1126N>A | p.Asp376Asn | p.D376N | Q92466 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DDB2 | SNV | Missense_Mutation | novel | c.1200C>A | p.Phe400Leu | p.F400L | Q92466 | protein_coding | deleterious(0) | possibly_damaging(0.808) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
DDB2 | SNV | Missense_Mutation | novel | c.1019N>C | p.Ile340Thr | p.I340T | Q92466 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DDB2 | SNV | Missense_Mutation | novel | c.1028N>T | p.Ala343Val | p.A343V | Q92466 | protein_coding | deleterious(0.01) | benign(0.023) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DDB2 | SNV | Missense_Mutation | novel | c.1276N>T | p.Arg426Trp | p.R426W | Q92466 | protein_coding | deleterious(0) | benign(0) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
DDB2 | SNV | Missense_Mutation | novel | c.863N>T | p.Arg288Met | p.R288M | Q92466 | protein_coding | deleterious(0.04) | benign(0.251) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |